Nanotechnology in reproductive medicine: Opportunities for clinical translation
Clinical and Experimental Reproductive Medicine · 01.12.2020 · 47 (4) · 245-262
DOI: 10.5653/cerm.2020.03650 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Experimental Reproductive Medicine, erschienen am 01.12.2020. Verfasst von Ruchita Shandilya und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Biology, ICMR-National Institute for Research in Environmental Health, Bhopal, India. Die Arbeit wurde bisher 61-mal zitiert (Crossref) und nennt 137 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Indian Council of Medical Research.
Abstract (Originalsprache)
In recent years, nanotechnology has revolutionized global healthcare and has been predicted to exert a remarkable effect on clinical medicine. In this context, the clinical use of nanomaterials for cancer diagnosis, fertility preservation, and the management of infertility and other pathologies linked to pubertal development, menopause, sexually transmitted infections, and HIV (human immunodeficiency virus) has substantial promise to fill the existing lacunae in reproductive healthcare. Of late, a number of clinical trials involving the use of nanoparticles for the early detection of reproductive tract infections and cancers, targeted drug delivery, and cellular therapeutics have been conducted. However, most of these trials of nanoengineering are still at a nascent stage, and better synergy between pharmaceutics, chemistry, and cutting-edge molecular sciences is needed for effective translation of these interventions from bench to bedside. To bridge the gap between translational outcome and product development, strategic partnerships with the insight and ability to anticipate challenges, as well as an in-depth understanding of the molecular pathways involved, are highly essential. Such amalgamations would overcome the regulatory gauntlet and technical hurdles, thereby facilitating the effective clinical translation of these nano-based tools and technologies. The present review comprehensively focuses on emerging applications of nanotechnology, which holds enormous promise for improved therapeutics and early diagnosis of various human reproductive tract diseases and conditions.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Molecular Biology, ICMR-National Institute for Research in Environmental Health, Bhopal, India.
- School of Life Sciences, University of Rajasthan, Jaipur, India.
- Division of Reproductive Biology, Maternal and Child Health, Indian Council of Medical Research, New Delhi, India.
Förderung
- Indian Council of Medical Research
Zitieren
APA
Shandilya, R., Pathak, N., Lohiya, N. K., Sharma, R. S., & Mishra, P. K. (2020). Nanotechnology in reproductive medicine: Opportunities for clinical translation. Clinical and Experimental Reproductive Medicine, 47(4), 245-262. https://doi.org/10.5653/cerm.2020.03650
Vancouver
Shandilya R, Pathak N, Lohiya NK, Sharma RS, Mishra PK. Nanotechnology in reproductive medicine: Opportunities for clinical translation. Clinical and Experimental Reproductive Medicine. 2020;47(4):245-262. doi:10.5653/cerm.2020.03650
BibTeX
@article{Shandilya2020,
author = {Shandilya, Ruchita and Pathak, Neelam and Lohiya, Nirmal Kumar and Sharma, Radhey Shyam and Mishra, Pradyumna Kumar},
title = {Nanotechnology in reproductive medicine: Opportunities for clinical translation},
journal = {Clinical and Experimental Reproductive Medicine},
year = {2020},
volume = {47},
number = {4},
pages = {245--262},
doi = {10.5653/cerm.2020.03650}
}
EUVIMED